Evidence map›Paper›PMID 36658640›Full record

ArticleBiological research2023

Synergistic effects of dendrosomal nanocurcumin and oxaliplatin on oncogenic properties of ovarian cancer cell lines by down-expression of MMPs.

Elahe Seyed Hosseini, Marziyeh Alizadeh Zarei, Hossein Tarrahimofrad, Javad Zamani, Hamed Haddad Kashani, Ejaz Ahmad, Hossein Nikzad

Open access · goldAbstract read
In one paragraph

Article in Biological research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Curcumin in ovarian cancer: mechanistic insights and translational potential.Medical oncology (Northwood, London, England) · 2026
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Elahe Seyed HosseiniGametogenesis Research Center, Institute for Basic Sciences, Kashan University of Medical Science, Kashan, Iran.
Marziyeh Alizadeh ZareiGametogenesis Research Center, Institute for Basic Sciences, Kashan University of Medical Science, Kashan, Iran. marziyehalizadeh91@yahoo.com.
Hossein TarrahimofradDepartment of Animal Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Javad ZamaniDepartment of Plant Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Hamed Haddad KashaniAnatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.
Ejaz AhmadDepartment of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
Hossein NikzadGametogenesis Research Center, Institute for Basic Sciences, Kashan University of Medical Science, Kashan, Iran. nikzad.kaums@gmail.com.ORCID http://orcid.org/0000-0002-5735-0162
Kashan University of Medical Sciences · IRNational Institute of Genetic Engineering and Biotechnology · IRMichigan Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundContrary to the advantageous anticancer activities of curcumin (Cur), limited bioavailability and solubility hindered its efficacy. Here, nontoxic dendrosomal nano carrier with Cur was used to overcome these problems. Despite considerable antitumor properties of Oxaliplatin (Oxa), the limiting factors are drug resistance and adverse side-effects. The hypothesis of this study was to evaluate the possible synergism between dendrosomal nanocurcumin (DNC) and Oxa and these agents showed growth regulatory effects on SKOV3 and OVCAR3 cells. METHODS AND MATERIALS: In the present study, colony formation, wound healing motility, cell adhesion, transwell invasion and migration assay and cell cycle arrest with or without DNC, Oxa and Combination were defined. In addition to, real time PCR and Western blot were used to analyze AKT, PI3K, PKC, JNK, P38 and MMPs mRNAs and proteins expressions. Docking of MMP-2-Cur, MMP-2-DNC and MMP-2-Oxa was performed and the results of all three complexes were simulated by molecular dynamics.

resultsOur findings illustrated that DNC had the greatest effect on cell death as compared to the Cur alone. Moreover, the growth inhibitory effects (such as cell death correlated to apoptosis) were more intense if Oxa was added followed by DNC at 4 h interval. However, insignificant effects were observed upon simultaneous addition of these two agents in both cell lines. Besides, a combination of agents synergistically alters the relative expression of MMP-9.

conclusionsThe docking results showed that His70 and Asp100 may play a key role at the MMP-2 binding site. The matrigel invasion as well as cell viability of ovarian cancer cell lines SKOV3 and OVCAR3 by DNC alone or in combination with Oxa was inhibited significantly. The inhibitory effects of these agents were due to the differential expression levels of MMP 2 and MMP 9 regulated by multiple downstream signaling cascades. From the molecular dynamic simulation studies, it was confirmed that DNC established a strong interaction with MMP-2.

Indexed as

CurcuminOvarian NeoplasmsApoptosisCell Line, TumorCell MovementCell ProliferationFemaleHumansMatrix Metalloproteinase 2OxaliplatinCurcuminMatrix Metalloproteinase 2OxaliplatinApoptosisCurcuminDendrosomal nanocurcuminMetastasisOvarian cancerOxaliplatin

Identifiers

PMID36658640
PMCPMC9854214
OpenAlexW4317486740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.